assembly biosciences (NASDAQ:ASMB) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
As previously announced, on November 28, 2016, Assembly
Biosciences, Inc. (the Company) agreed upon a transition plan
with Dr. Lee D. Arnold, the Companys Chief Discovery Officer, in
connection with the end of Dr. Arnolds employment with the
Company. On December 7, 2016, the Company and Dr. Arnold entered
into a Separation Agreement (the Agreement) providing for the
terms of such transition. to the Agreement, in addition to the
separation benefits provided for to Dr. Arnolds Employment
Agreement dated July 11, 2014 with the Company, Dr. Arnold will
be entitled to receive his base salary and reimbursement of COBRA
premiums for an additional four months if he provides certain
transition and consulting services as requested, to the
Agreement.
A copy of the Agreement is filed as Exhibit 10.1 hereto and is
incorporated by reference in this Form 8-K. The description above
is qualified in its entirety by reference to the full text of the
Agreement.
| Item 9.01 | Financial Statements and Exhibits |
(d)Exhibits.
| ExhibitNo. | Description | |
| 10.1 |
Separation Agreement between Assembly Biosciences, Inc. and Dr. Lee D. Arnold dated December 7, 2016 |
About assembly biosciences (NASDAQ:ASMB)
Assembly Biosciences, Inc. is a biotechnology company. The Company is engaged in developing approximately two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral biological therapeutics, which are designed to restore health to a dysbiotic microbiome. It has discovered various core protein Allosteric Modulators (CpAMs), which are small molecules that directly target and allosterically modulate a number of Hemoglobin C functions. The Microbiome Program consists of an integrated platform that includes a strain identification and selection process, methods for strain isolation and growth under current good manufacturing practice (cGMP) conditions, and a delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal tract. The lead program from this platform, AB-M101, is in development for the treatment of C. difficile-infections. assembly biosciences (NASDAQ:ASMB) Recent Trading Information
assembly biosciences (NASDAQ:ASMB) closed its last trading session down -0.05 at 13.37 with 19,259 shares trading hands.